Evidence map›Paper›PMID 30604599›Full record

Trial reportDiabetes & metabolism journal2019

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.

Hae Kyung Yang, Seung Hwan Lee, Juyoung Shin, Yoon Hee Choi, Yu Bae Ahn, Byung Wan Lee, Eun Jung Rhee, Kyung Wan Min, Kun Ho Yoon

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & metabolism journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  5. Review
  6. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.Current protein & peptide science · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hae Kyung YangDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-8154-4090
Seung Hwan LeeDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Juyoung ShinDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yoon Hee ChoiDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yu Bae AhnDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Byung Wan LeeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Eun Jung RheeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kyung Wan MinDivision of Endocrinology and Metabolism, Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
Kun Ho YoonDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-9109-2208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe evaluated the efficacy and safety of acarbose add-on therapy in Korean patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with metformin and sitagliptin.

methodsA total of 165 subjects were randomized to metformin and sitagliptin (Met+Sita,

resultsThe add-on of acarbose (Met+Sita+Acarb group) demonstrated a 0.44%±0.08% (P<0.001 vs. baseline) decrease in glycosylated hemoglobin (HbA1c) at week 16, while changes in HbA1c were insignificant in the Met+Sita group (-0.09%±0.10%,

conclusionIn conclusion, a 16-week acarbose add-on therapy to metformin and sitagliptin, effectively lowered HbA1c without significant adverse events. Acarbose might be a good choice as a third-line therapy in addition to metformin and sitagliptin in Korean subjects with T2DM who have predominant postprandial hyperglycemia and a high carbohydrate intake.

Indexed as

AcarboseBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleHumansHypoglycemic AgentsMaleMetforminMiddle AgedSitagliptin PhosphateTreatment OutcomeAcarboseBlood GlucoseHypoglycemic AgentsMetforminSitagliptin PhosphateAcarboseDiabetes mellitus, type 2Drug therapy, combinationMetforminSitagliptin phosphate

Identifiers

PMID30604599
PMCPMC6581543

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.